Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - cetuximab, quantity: 5 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; citric acid monohydrate; polysorbate 80; sodium chloride; sodium hydroxide; glycine - erbitux is indicated for the treatment of patients with epidermal growth factor receptor (egfr)-expressing, ras wild-type metastatic colorectal cancer. in combination with infusional 5-fluorouracil/folinic acid plus irinotecan. in combination with irinotecan in patients who are refractory to first-line chemotherapy. in first-line in combination with folfox. as a single agent in patients who have failed or are intolerant to oxaliplatin-based therapy and irinotecan-based therapy. (see clinical trials) erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck. in combination with radiation therapy for locally advanced disease. in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - oxaliplatin, quantity: 100 mg - injection, intravenous infusion - excipient ingredients: tartaric acid; water for injections; sodium hydroxide - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - oxaliplatin, quantity: 50 mg - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; tartaric acid - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - olive oil, quantity: 32 g/l; soya oil, quantity: 8 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; water for injections; sodium hydroxide; egg lecithin; nitrogen; glycerol - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 8 g/l; olive oil, quantity: 32 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; egg lecithin; water for injections; glycerol; nitrogen; sodium hydroxide - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 8 g/l; olive oil, quantity: 32 g/l - injection, intravenous infusion - excipient ingredients: water for injections; nitrogen; sodium hydroxide; sodium oleate; glycerol; egg lecithin - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 8 g/l; olive oil, quantity: 32 g/l - injection, intravenous infusion - excipient ingredients: egg lecithin; sodium oleate; sodium hydroxide; glycerol; water for injections; nitrogen - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 8 g/l; olive oil, quantity: 32 g/l - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; nitrogen; egg lecithin; glycerol; sodium oleate - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: egg lecithin; glycerol; sodium oleate; water for injections; sodium hydroxide; dl-alpha-tocopherol - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; soya oil, quantity: 60 g/l; olive oil, quantity: 50 g/l; medium chain triglycerides, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; water for injections; egg lecithin; dl-alpha-tocopherol; sodium hydroxide; glycerol - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.